To accelerate commercialisation of new medicines
The Canadian Centre for Commercialisation of Regenerative Medicine (CCRM) and the UK’s Cell Therapy Catapult (CTC) have agreed to work together on the development and commercialisation of cell therapy and regenerative medicine opportunities from the discoveries emerging in their respective countries.
The two organisations will work together on suitable R&D projects, clinical trials, standardisation and regulatory efforts, as well as initiatives such as training. The Canadian and UK governments have identified cell therapy and regenerative medicine for its potential ability to increase each nation’s health and wealth.
‘CCRM and the Cell Therapy Catapult are both committed to moving potential therapeutic approaches from early stage research to the marketplace and there are many good arguments for combining our strengths and resources, and doing this together,’ said Michael May, CEO of CCRM. ‘If we can commercialise research faster and more effectively by partnering, then everyone benefits – especially the patient.’
Keith Thompson, CEO of the Cell Therapy Catapult, added: ‘The anticipated exchange of ideas and technological expertise, as well as collaborative activity, will be of great benefit to patients and the cell therapy industries in both countries.’